Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysis

12 Jun 2019

Abstract excerpt

OBJECTIVE: Non-invasive prenatal testing (NIPT) based on cell-free fetal DNA (cffDNA) is highly accurate in the detection of common fetal autosomal trisomies. Aim of this project was to investigate short-term costs and clinical outcomes of the contingent use of cffDNA for prenatal screening of trisomies 21, 18, 13 within a national health service (NHS). METHODS: An economic analysis was developed from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fetal and Pediatric Neurological Disorders
Share to Genomic variations and chromosomal abnormalities
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31188879
DOI: 10.1371/journal.pone.0218166

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysisPMID 31188879Read ↗

Screening Performance and Costs of Different Strategies in Prenatal Screening for Trisomy 21Semantic proximity Read ↗

Combined First Trimester Screening and Cell-Free Fetal DNA – “Next Generation Screening”Semantic proximity Read ↗

Clinical implementation of routine screening for fetal trisomies in the UK NHS : cell‐free DNA test contingent on results from first‐trimester combined testSemantic proximity Read ↗

An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy PopulationSemantic proximity Read ↗

Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screeningSemantic proximity Read ↗

First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testingSemantic proximity Read ↗

Current controversies in prenatal diagnosis: Expanded NIPT that includes conditions other than trisomies 13, 18, and 21 should be offeredSemantic proximity Read ↗

Performance of cell-free DNA sequencing-based non-invasive prenatal testing: experience on 36,456 singleton and multiple pregnanciesSemantic proximity Read ↗

Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot studySemantic proximity Read ↗

Noninvasive Prenatal Testing - When Is It Advantageous to ApplySemantic proximity Read ↗

<scp>UK NHS</scp> pilot study on cell‐free <scp>DNA</scp> testing in screening for fetal trisomies: factors affecting uptakeSemantic proximity Read ↗

The ethical landscape(s) of non-invasive prenatal testing in England, France and Germany: findings from a comparative literature reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.